Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

BACKGROUND: Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology. The aim of this study was to identify novel epigenetic biomarkers a...

Descripción completa

Detalles Bibliográficos
Autores principales: Palomeras, Sònia, Diaz-Lagares, Ángel, Viñas, Gemma, Setien, Fernando, Ferreira, Humberto J., Oliveras, Glòria, Crujeiras, Ana B., Hernández, Alejandro, Lum, David H., Welm, Alana L., Esteller, Manel, Puig, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612099/
https://www.ncbi.nlm.nih.gov/pubmed/31277676
http://dx.doi.org/10.1186/s13058-019-1160-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612099/
https://www.ncbi.nlm.nih.gov/pubmed/31277676
http://dx.doi.org/10.1186/s13058-019-1160-x

Ejemplares similares